Principles of Clinical and Engineering Integration in Hemocompatibility - Biomaterials Science: An Integrated Clinical and Engineering Approach - page 26

42. Cugno M, Borghi MO, Lonati LM, Ghiadoni L, Gerosa M, Grossi C, De Angelis V,
et al. 2010. Patients with antiphospholipid syndrome display endothelial per-
turbation. J Autoimmun. 34(2): 105-10.
43. Pierangeli SS, Colden-Stanfield M, Liu X, Barker JH, Anderson GL, Harris EN.
1999. Antiphospholipid antibodies from antiphospholipid syndrome patients
activate endothelial cells in vitro and in vivo. Circulation 99(15): 1997-2002.
44. Allen KL, Hamik A, Jain MK, McCrae KR. 2011. Endothelial cell activation by
antiphospholipid antibodies is modulated by Kruppel-like transcription fac-
tors. Blood J 117(23): 6383-6391. [Epub ahead of print].
45. Simantov E, LaSala J, Lo SK, Gharavi AE, Sammaritano LR, Salmon JE, Silverstein
RL. 1995. Activation of cultured vascular endothelial cells by antiphospholipid
antibodies. J Clin Invest 96: 2211-2219.
46. Del Papa N, Guidali L, Spatola L, Bonara P, Borghi MO, Tincani A, Balestrieri G,
Meroni PL. 1995. Relationship between anti-phospholipid and anti-endothelial
cell antibodies: b2 glycoprotein I mediates the antibody binding to endothe-
lial membranes and induces the expression of adhesion molecules. Clin Exp
Rheumatol 13: 179-185.
47. Heublein B, Rohde R, Kaese V, Niemeyer M, Hartung W, Haverich A. 2003.
Biocorrosion of magnesium alloys: A new principle in cardiovascular implant
technology? Heart 89: 651-56.
48. Peeters P, Bosiers M, Verbist J, Deloose K, Heublein B. 2005. Preliminary results
after application of absorbable metal stents in patients with critical limb isch-
emia. J Endovasc Ther 12: 1-5.
49. Zartner P, Cesnjevar R, Singer H, Weyand M. 2005. First successful implantation
of a biodegradable metal stent into the left pulmonary artery of a preterm baby.
Catheter Cardiovasc Interv 66: 590-94.
50. Stack RE, Califf RM, Phillips HR, et al. 1988. Interventional cardiac catheteriza-
tion at Duke Medical Center. Am J Cardiol 62 (suppl F): 3F-24.
51. Waksman R, Pakala R, Kuchulakanti PK, et al. 2006. Safety and efficacy of
bioabsorbable magnesium alloy stents in porcine coronary arteries. Catheter
Cardiovasc Interv 68: 606-17.
52. Peuster M, Wohlsein P, Brugmann M, et al. 2001. A novel approach to temporary
stenting: Degradable cardiovascular stents produced from corrodible metal-
results 6-18 months after implantation into New Zealand white rabbits. Heart
86: 563-69.
53. Balcon R, Beyar R, Chierchia S, et al. 1997. Recommendations on stent manufac-
ture, implantation and utilization. Eur Heart J 18: 1536-47.
54. Waksman R, Pakala R, Baffour R, Seabron R, Hellinga D, Tio FO. 2008. Short-
term effects of biocorrodible iron stents in porcine coronary arteries. J Interv
Cardiol 21: 15-20.
55. Hermawan H, Alamdari H, Mantovani D, Dubé D. 2008. Iron-manganese:
New class of degradable metallic biomaterials prepared by powder metallurgy.
Powder Metall 51: 38-45.
56. Peuster M, Hesse C, Schloo T, Fink C, Beerbaum P, von Schnakenburg C. 2006.
Longterm biocompatibility of a corrodible peripheral iron stent in the porcine
descending aorta. Biomaterials 27: 4955-62.
57. Erbel R, Di Mario C, Bartunek J, et al. 2007. PROGRESS-AMS (Clinical
Performance and Angiographic Results of Coronary Stenting with Absorbable
Metal Stents) Investigators. Temporary scaffolding of coronary arteries with